Navidea Biopharmaceuticals (NAVB) Tops Q1 EPS by 2c

Navidea Biopharmaceuticals (NYSE: NAVB) reported Q1 EPS of ($0.08), $0.02 better than the analyst estimate of ($0.10). Revenue for the quarter came in at $752 thousand versus the consensus estimate of $900 thousand.

For earnings history and earnings-related data on Navidea Biopharmaceuticals (NAVB) click here.

You May Also Be Interested In

• L3Harris CEO steps down amid conduct review, shares drop
• UBS: 'We expect SpaceX shares to continue to trade on demand for tokens'
• Grocery Outlet Holding (GO) PT Raised to $11.50 at UBS